Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SQUIBB RESEARCH ON CAPTOPRIL FOR DIABETIC THERAPY

Executive Summary

SQUIBB RESEARCH ON CAPTOPRIL FOR DIABETIC THERAPY will begin in February, according to the firm. A study comparing the effects of captopril to hydrochlorothiazide on proteinuria (protein in the urine) is being designed to evaluate captopril's usefulness in slowing the progression of chronic renal disease, a consequence of diabetes. The planned Squibb study will follow a Dec. 26, 1985 New England Journal of Medicine report by a Japanese medical team which found that "the inhibition of angiotensin-converting enzyme by captopril relieves intrarenal hypertension . . . ]which[ decreased urinary protein excretion." Though "the follow-up period in ]the[ study was not long enough" to determine whether captopril could delay the need for dialysis, the researchers from Sendai Shakaihoken Hospital, Japan, concluded that, "many advantages can be obtained if serious proteinuria can be improved promptly by the administration of captopril." The diabetic study on Capoten (captopril) could be particularly interesting in light of the drug's initial labeling. When the product was originally approved by FDA, the agency expressed concern about high proteinuria. Capoten labeling contains a warning about proteinuria and advises that urinary protein estimates be obtained prior to therapy.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

MT003605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel